Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for Microcirculation in Septic Shock
NCT05141071Phase 2Completed
- Sponsor
- Cairo University
- Start
- Nov 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in septic shock comparing Ivabradine with Placebo (2 arms). Primary endpoint: Microvascular Flow Index at 6 hours. Started Nov 2021; status: completed.
02
Drugs
ivabradine
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05141071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141071.